Nabla Bio

nabla.bio

We develop AI and wet-lab technologies that enable the rational design of developable, selective, and functional drugs against previously undruggable targets. To maximize the patient impact of our platform, we collaborate with leading pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb, and Takeda, to expand their pipelines with high-quality drug candidates. If successful, we could double the number of disease-relevant drug targets the industry advances for drug development. Since launching in 2021, we have raised $37 million with the backing of leading investors, including Radical Ventures, Khosla Ventures, and Zetta Venture Partners. Our technical team is based in Cambridge, Massachusetts, and continues to recruit top machine learning and synthetic biology talent. For more information, check out the careers section of our website at www.nabla.bio.